Quest introduces first-to-market consumer-initiated blood test for alzheimer's disease risk assessment on questhealth.com

Ad-detect™ test for alzheimer's disease is the first blood-based biomarker test for assessing beta amyloid protein, a recognized marker of alzheimer's disease, available for consumer purchase to help individuals identify their risk of developing alzheimer's disease physician oversight included in offering, helping individuals interpret results and determine next steps secaucus, n.j. , july 31, 2023 /prnewswire/ -- quest diagnostics (nyse: dgx), the leader in diagnostic information services, today announced the availability of the ad-detect™ test for alzheimer's disease on questhealth.com – the first blood test available for consumer purchase that helps assess potential risk of developing alzheimer's disease based on a brain protein that contributes to the condition.
DGX Ratings Summary
DGX Quant Ranking